Get the Stockscreener App
62.38
1.35%
0.83
After Hours:
60.57
-1.81
-2.90%
Arrowhead Pharmaceuticals Inc stock is traded at $62.38, with a volume of 2.32M.
It is up +1.35% in the last 24 hours and down -5.38% over the past month.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
See More
Previous Close:
$61.55
Open:
$61.73
24h Volume:
2.32M
Relative Volume:
0.77
Market Cap:
$8.74B
Revenue:
$181.74M
Net Income/Loss:
$-143.97M
P/E Ratio:
-44.88
EPS:
-1.39
Net Cash Flow:
$9.60M
1W Performance:
-3.50%
1M Performance:
-5.38%
6M Performance:
+250.45%
1Y Performance:
+235.92%
1-Day Range:
$61.17
$63.13
1-Week Range:
$60.34
$68.44
52-Week Range:
$9.57
$76.76
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Name
Arrowhead Pharmaceuticals Inc
Sector
Industry
Phone
626-696-4702
Address
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
62.38 | 8.62B | 181.74M | -143.97M | 9.60M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-24 | Initiated | Goldman | Neutral |
| Dec-04-23 | Initiated | BofA Securities | Buy |
| Sep-19-23 | Initiated | Citigroup | Neutral |
| Jul-21-23 | Initiated | TD Cowen | Outperform |
| May-12-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-12-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-11-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-19-22 | Resumed | Goldman | Buy |
| Aug-06-21 | Reiterated | Chardan Capital Markets | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-19-20 | Initiated | Citigroup | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| May-08-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-15-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-24-20 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Mar-17-20 | Initiated | Goldman | Neutral |
| Jan-21-20 | Initiated | SVB Leerink | Underperform |
| Dec-13-19 | Initiated | Oppenheimer | Perform |
| Nov-29-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-27-19 | Reiterated | B. Riley FBR | Buy |
| Nov-25-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-24-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-22-19 | Reiterated | Chardan Capital Markets | Buy |
| Oct-03-19 | Initiated | Robert W. Baird | Outperform |
| Sep-07-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Sep-06-18 | Reiterated | Chardan Capital Markets | Buy |
| Aug-08-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-02-18 | Reiterated | Chardan Capital Markets | Buy |
View All
Arrowhead Pharmaceuticals Inc Stock (ARWR) Latest News
Equities Analysts Issue Forecasts for ARWR Q2 Earnings - MarketBeat
Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Strong Earnings Are Of Good Quality - simplywall.st
The Strong Earnings Posted By Arrowhead Pharmaceuticals (NASDAQ:ARWR) Are A Good Indication Of The Strength Of The Business - 富途牛牛
Understanding the Setup: (ARWR) and Scalable Risk - Stock Traders Daily
ARWR: Strong Start for REDEMPLO Commercialization - Smartkarma
ARWR: Strong Start for REDEMPLO Commercialization… - Yahoo Finance
Arrowhead Pharmaceuticals' (ARWR) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Arrowhead Pharma (ARWR) Receives Buy Rating from HC Wainwright | - GuruFocus
Breaking Down Arrowhead Pharma: 18 Analysts Share Their Views - Benzinga
Goldman Sachs Maintains Neutral on ARWR Arrowhead Pharmaceuticals Feb 2026 - Meyka
Arrowhead Pharmaceuticals stock swings as S&P MidCap 400 move lands and Goldman flags 2026 catalysts (ARWR) - TechStock²
Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline Overview: Insights into 80+ Leading Companies and 100+ Novel Treatments | DelveInsight - GlobeNewswire Inc.
Arrowhead Pharma stock outlook: Goldman Sachs sees 2026 catalysts ahead - Investing.com
Arrowhead Pharmaceuticals, Inc.(NasdaqGS: ARWR) added to S&P 400Biotechnology - marketscreener.com
Top Pharmaceutical Stocks To Follow TodayFebruary 8th - MarketBeat
Arrowhead Pharmaceuticals Earnings Call Flags Pivotal 2026 - TipRanks
Best Pharmaceutical Stocks To Add to Your WatchlistFebruary 7th - MarketBeat
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After A Strong 1 Year Shareholder Return - Yahoo Finance
Principal Financial Group Inc. Buys 157,035 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals (ARWR) Q1 Profit Challenges Bearish Narratives On Earnings Quality - Sahm
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2026 Earnings Call Transcript - Insider Monkey
Arrowhead gains approval of Redemplo in China for high triglycerides - MSN
More Rivalry With Ionis In A Potentially ‘Transformational’ Year For Arrowhead - Citeline News & Insights
Arrowhead’s RNAi Platform Shifts Toward Commercialization And Broader Partnerships - Sahm
Arrowhead Pharmaceuticals (ARWR) Reports Strong Q1 2026 Performa - GuruFocus
Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results - BioSpace
Decoding Arrowhead Pharmaceuticals Inc (ARWR): A Strategic SWOT Insight - GuruFocus
Earnings Call Summary | Arrowhead Pharmaceuticals(ARWR.US) Q1 2026 Earnings Conference - 富途牛牛
Arrowhead Pharmaceuticals Inc (ARWR) Q1 2026 Earnings Call Highl - GuruFocus
Arrowhead Pharmaceuticals Inc (ARWR) Q1 2026 Earnings Call Highlights: Strong Financial ... By GuruFocus - Investing.com Canada
Arrowhead Pharmaceuticals Q1 Earnings Call Highlights - MarketBeat
Earnings call transcript: Arrowhead Pharmaceuticals beats Q1 2026 EPS forecast - Investing.com India
Arrowhead (ARWR) Q1 2026 Earnings Call Transcript - The Globe and Mail
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Issues Quarterly Earnings Results - MarketBeat
Earnings Flash (ARWR) Arrowhead Pharmaceuticals, Inc. Reports Q1 Revenue $264.0M, vs. FactSet Est of $213.9M - marketscreener.com
Arrowhead (ARWR) Set to Join S&P 400 Index - GuruFocus
Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600 - Yahoo Finance
Is Arrowhead Pharmaceuticals (ARWR) Pricing Reflect Recent RNAi Progress And Strong Share Price Gains? - Sahm
Trading Action: Is Arrowhead Pharmaceuticals Inc gaining market share2025 Institutional Moves & Low Risk Entry Point Tips - baoquankhu1.vn
Why Arrowhead Pharmaceuticals (ARWR) Is Up 7.8% After Launching Its First Dual-Gene RNAi Trial - Yahoo Finance
Arrowhead Stock Has Skyrocketed 290% in One Year, and One Fund Trimmed Its Holdings by $4 Million - AOL.com
Arrowhead Pharmaceuticals (ARWR) Valuation After First Human Dosing Of Dual Gene RNAi Therapy For Mixed Hyperlipidemia - Sahm
The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following First Dual-Gene RNAi Cardio Trial Initiation - Sahm
The Technical Signals Behind (ARWR) That Institutions Follow - Stock Traders Daily
Arrowhead Pharmaceuticals at Risk: Potential Generic Competition Threatens REDEMPLO’s Market Exclusivity - MSN
Arrowhead Pharmaceuticals, Inc. $ARWR is Privium Fund Management B.V.'s 9th Largest Position - MarketBeat
Arrowhead gains, Agios drops as drug developers end 2025 up 34% - BioWorld MedTech
Can Arrowhead Pharmaceuticals Inc. weather a recessionJuly 2025 Catalysts & Accurate Entry/Exit Alerts - Mfd.ru
Is Arrowhead Pharmaceuticals Inc. stock a buy or sellLayoff News & Precise Swing Trade Entry Alerts - mfd.ru
How cyclical is Arrowhead Pharmaceuticals Inc.’s revenue stream2025 Valuation Update & Scalable Portfolio Growth Ideas - Mfd.ru
Arrowhead Pharmaceuticals (ARWR) to Release Quarterly Earnings on Thursday - MarketBeat
Arrowhead Pharmaceuticals Inc Stock (ARWR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Arrowhead Pharmaceuticals Inc Stock (ARWR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hamilton James C | Chief Medical Officer |
Jan 05 '26 |
Sale |
63.11 |
40,164 |
2,534,661 |
171,958 |
| Anzalone Christopher Richard | Chief Executive Officer |
Jan 02 '26 |
Sale |
66.10 |
13,187 |
871,703 |
3,792,739 |
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):